Damora Therapeutics (DMRA) Change in Account Payables (2019 - 2026)
Damora Therapeutics posted quarterly Change in Account Payables of $375000.0 for Q1 2026, up 1730.43% year-on-year from $20486.9 in Q1 2025, and up 507.61% on a QoQ basis from -$92000.0 in Q4 2025.
Damora Therapeutics (DMRA) has 8 years of Change in Account Payables data on file, last reported at $375000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables rose 1730.43% year-over-year to $375000.0; the trailing twelve-month figure through Mar 2026 stood at $449000.0 (up 134.25% YoY), and the FY2025 full-year result was $51000.0, up 103.85% from the prior year.
- Change in Account Payables for Q1 2026 stood at $375000.0, up from -$92000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $2.0 million in Q2 2023 and bottomed at -$2.8 million in Q4 2023.
- The 5-year median for Change in Account Payables is -$92000.0 (2025), against an average of -$42823.5.
- The widest annual swing landed in 2022, when Change in Account Payables sank 329.87%; it then soared 1730.43% in 2026.
- A 5-year view of Change in Account Payables shows it stood at $1.4 million in 2022, then tumbled by 292.31% to -$2.8 million in 2023, then surged by 95.46% to -$126000.0 in 2024, then advanced by 26.98% to -$92000.0 in 2025, then soared by 507.61% to $375000.0 in 2026.
- The last three Change in Account Payables figures came in at $375000.0 (Q1 2026), -$92000.0 (Q4 2025), and -$236000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -3.26 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 35.60 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Damora Therapeutics | 853.36 Mn | 650.97 Mn | - | 375,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 375,000.00 |
| Mar 31, 2026 | 375,000.00 |
| Dec 31, 2025 | -92,000.00 |
| Dec 31, 2025 | -92,000.00 |
| Sep 30, 2025 | -236,000.00 |
| Sep 30, 2025 | -236,000.00 |
| Jun 30, 2025 | 402,000.00 |
| Jun 30, 2025 | 402,000.00 |
| Mar 31, 2025 | -23,000.00 |
| Mar 31, 2025 | -23,000.00 |
| Dec 31, 2024 | -126,000.00 |
| Dec 31, 2024 | -126,000.00 |
| Sep 30, 2024 | -221,000.00 |
| Sep 30, 2024 | -221,000.00 |
| Jun 30, 2024 | -941,000.00 |
| Jun 30, 2024 | -941,000.00 |
| Mar 31, 2024 | -37,000.00 |
| Mar 31, 2024 | -37,000.00 |
| Dec 31, 2023 | -2.78 Mn |
| Dec 31, 2023 | -2.78 Mn |
| Sep 30, 2023 | -1.08 Mn |
| Sep 30, 2023 | -1.08 Mn |
| Jun 30, 2023 | 2.01 Mn |
| Jun 30, 2023 | 2.01 Mn |
| Mar 31, 2023 | 200,000.00 |
| Mar 31, 2023 | 200,000.00 |
| Dec 31, 2022 | 1.44 Mn |
| Dec 31, 2022 | 1.44 Mn |
| Sep 30, 2022 | -908,000.00 |
| Sep 30, 2022 | -908,000.00 |
| Jun 30, 2022 | -400,000.00 |
| Jun 30, 2022 | -400,000.00 |
| Mar 31, 2022 | 1.68 Mn |
| Mar 31, 2022 | 1.68 Mn |
| Dec 31, 2021 | -449,000.00 |
| Dec 31, 2021 | -449,000.00 |
| Sep 30, 2021 | 395,000.00 |
| Sep 30, 2021 | 395,000.00 |
| Jun 30, 2021 | -197,000.00 |
| Jun 30, 2021 | -197,000.00 |
| Mar 31, 2021 | -1.07 Mn |
| Mar 31, 2021 | -1.07 Mn |
| Dec 31, 2020 | -1.61 Mn |
| Dec 31, 2020 | -1.61 Mn |
| Sep 30, 2020 | 2.72 Mn |
| Sep 30, 2020 | 2.72 Mn |
| Jun 30, 2020 | 136,000.00 |
| Jun 30, 2020 | 136,000.00 |
| Mar 31, 2020 | -1.72 Mn |
| Mar 31, 2020 | -1.72 Mn |
| Dec 31, 2019 | 2.70 Mn |
| Dec 31, 2019 | 2.70 Mn |